The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
Open accessAbstract
BACKGROUNDLipoprotein(a) levels are genetically determined and, when elevated, are a risk factor for cardiovascular disease and aortic stenosis.There are no approved pharmacologic therapies to lower lipoprotein(a) levels. METHODSWe conducted a randomized, double-blind, placebo-controlled, dose-ranging trial involving 286 patients with established cardiovascular disease and screening lipoprotein(a) levels of at least 60 mg per deciliter (150 nmol per liter).Patients received the hepatocyte-directed antisense oligonucleotide AKCEA-APO(a)-L Rx , referred to here as APO(a)-L Rx (20, 40, or 60 mg every 4 weeks; 20 mg every 2 weeks; or 20 mg every week), or saline placebo subcutaneously for 6 to 12 months.The lipoprotein(a) level was measured with an isoform-independent assay.The primary end point was the percent change in lipoprotein(a) level from baseline to month 6 of exposure (week 25 in the groups that received monthly doses and week 27 in the groups that received more frequent doses). RESULTSThe median baseline lipoprotein(a) levels in the six groups ranged from 204.5 to 246.6 nmol per liter.Administration of APO(a)-L Rx resulted in dose-dependent decreases in lipoprotein(a) levels, with mean percent decreases of 35% at a dose of 20 mg every 4 weeks, 56% at 40 mg every 4 weeks, 58% at 20 mg every 2 weeks, 72% at 60 mg every 4 weeks, and 80% at 20 mg every week, as compared with 6% with placebo (P values for the comparison with placebo ranged from 0.003 to <0.001).There were no significant differences between any APO(a)-L Rx dose and placebo with respect to platelet counts, liver and renal measures, or influenza-like symptoms.The most common adverse events were injection-site reactions.CONCLUSIONS APO(a)-L Rx reduced lipoprotein(a) levels in a dose-dependent manner in patients who had elevated lipoprotein(a) levels and established cardiovascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“At the same time, pelacarsen was well tolerated. Only injection site reactions were more frequently observed in the treatment group.”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [182]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Consistently, in a randomized, double-blind, placebo-controlled phase 2 trial of 286 patients with elevated Lp(a) levels and established CVD, pelacarsen reduced Lp(a) in a dose-dependent manner by up to − 80% from baseline [182].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [182]
The cited source says what the claim attributes to it.
In the citing paper
“Lp(a) has been identified as an independent risk marker for CVD as it exerts pro-atherogenic, pro-inflammatory, and pro-thrombotic effects which may play a critical role in the pathogenesis of atherosclerosis [182].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [182]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.002 · Cited by 1,751
A NEW SERUM TYPE SYSTEM IN MAN—THE Lp SYSTEM
Berg, K. (1963) · Acta Pathologica Microbiologica Scandinavica · doi:10.1111/j.1699-0463.1963.tb01808.x · Cited by 1,383
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial
O’Donoghue, M. L., Fazio, S., Giugliano, R. P., Stroes, E. S. G., Kanevsky, E., Gouni-Berthold, I., Im, K., Lira Pineda, A., Wasserman, S. M., Češka, R., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.037184 · Cited by 984
Self-citationCrooke, S. T., Witztum, J. L., Bennett, C. F., & Baker, B. F. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.004 · Cited by 841
Self-citationViney, N. J., van Capelleveen, J. C., Geary, R. S., Xia, S., Tami, J. A., Yu, R. Z., Marcovina, S. M., Hughes, S. G., Graham, M. J., Crooke, R. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31009-1 · Cited by 754
Self-citationvan der Valk, F. M., Bekkering, S., Kroon, J., Yeang, C., den Bossche, J. V., van Buul, J. D., Ravandi, A., Nederveen, A. J., Verberne, H. J., Scipione, C. A., et al. (2016) · Circulation · doi:10.1161/circulationaha.116.020838 · Cited by 706
Self-citationLipoprotein Lp(a) and the risk for myocardial infarction
Kostner, G. M., Avogaro, P., Cazzolato, G., Marth, E., Bittolo-Bon, G., & Qunici, G. B. (1981) · Atherosclerosis · doi:10.1016/0021-9150(81)90103-9 · Cited by 687
Giugliano, R. P., Pedersen, T. R., Park, J.-G., De Ferrari, G. M., Gaciong, Z. A., Ceska, R., Toth, K., Gouni-Berthold, I., Lopez-Miranda, J., Schiele, F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32290-0 · Cited by 682
Self-citationStructure, function, and genetics of lipoprotein (a)
Schmidt, K., Noureen, A., Kronenberg, F., & Utermann, G. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r067314 · Cited by 671
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 1,001
Lipoprotein(a) is a Prevalent yet Vastly Underrecognized Risk Factor for Cardiovascular Disease
Rendler, J., Murphy, M., & Yeang, C. (2024) · ASEAN Journal of Psychiatry · doi:10.54615/2231-7805.397 · Cited by 8
Burvill, A., Watts, G. F., Norman, R., & Ademi, Z. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.08.012 · Cited by 8
Abdalla, H., Mahmoud, A., Khedr, A. E., Farina, J., Scalia, I. G., Abbas, M. T., Awad, K., Ali, N. B., Bismee, N. N., Esfahani, S. A., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011029 · Cited by 9
Lipoprotein(a) Is Elevated and Inversely Related to Coronary Endothelial Function in People With HIV
Kikuchi, D. S., Kwapong, Y. A., Schär, M., Weiss, R. G., Sun, K. M., Brown, T. T., Piggott, D. A., Minhas, A., Gerstenblith, G., Soleimani‐Fard, A., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.035975 · Cited by 8
New Approaches to Lipoproteins for the Prevention of Cardiovascular Events
Fujino, M., Giovanni, G. D., & Nicholls, S. J. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv22031 · Cited by 8
Jean-Gilles, M., & Gencer, B. (2025) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000981 · Cited by 8
Bhatia, H. S., Dalal, S., & Ross, E. (2025) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000999 · Cited by 8
Integrating New Technologies in Lipidology: A Comprehensive Review
Escobar, C., García, J. S., Torremocha, A., Lorenzo, C. C., Lara-García, A., Muñoz, L. C., González, R. M., García, J. V., & Banach, M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14144984 · Cited by 10
Lipoprotein (a) in primary cardiovascular disease prevention is actionable today
Parcha, V., & Bittner, V. (2025) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2025.100581 · Cited by 9
Lipoprotein(a) and Venous Thromboembolism: Association, Causality, and Medications
Pfeferman, M. B., Rashedi, S., Lip, G. Y. H., Weber, C., O’Donoghue, M. L., Nissen, S. E., Nicholls, S. J., Natarajan, P., Plutzky, J., Libby, P., et al. (2025) · Thrombosis and Haemostasis · doi:10.1055/a-2674-5114 · Cited by 10
Cinezan, C., Măgureanu, D. C., Hiceag, M. L., Rus, C. B., Ilias, I. T., Bogdan, I. D., Buzle, A. M., & Cozma, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178163 · Cited by 8
Diabetes Mellitus and Lipoprotein(a): A Determinant Interaction in Micro- and Macrovascular Damage
Polo-Barranco, A., Rebolledo-Maldonado, C., Esquiaqui-Rangel, V., Nuñez-Mejia, A., Rambal-Torres, J., Barraza-Ahumada, V., Vargas-Cantillo, S., la Cruz, W. B.-D., Liñán-Martínez, V., Rada-Obeso, V., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311427 · Cited by 8
Emerging therapies targeting lipoprotein(a): the next frontier in cardiovascular risk reduction
Alhomoud, I. S. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1727918 · Cited by 10
Oikonomou, E. K., Craig, N. J., Holste, G., Shankar, S. V., White, A. C., Mahendran, M., Newby, D. E., Dweck, M. R., & Khera, R. (2025) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.125.018353 · Cited by 9
Mulligan, M. D., Gandhi, R. S., Vishwakarma, R., & Bhattacharya, R. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.03.019 · Cited by 8
Oxyphospholipids in Cardiovascular Calcification
Chignon, A., Bon-Baret, V., Boulanger, M., Bossé, Y., & Mathieu, P. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.313790 · Cited by 8
Genetic Lipid Disorders Associated with Atherosclerotic Cardiovascular Disease
Mszar, R., Webb, G., Kulkarni, V., Ahmad, Z., & Soffer, D. E. (2022) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.11.009 · Cited by 8
Considerations for routinely testing for high lipoprotein(a)
Nurmohamed, N. S., Moriarty, P. M., & Stroes, E. S. G. (2022) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000838 · Cited by 8
Self-citationJacobsen, A. P., Whelton, S. P., Blumenthal, R. S., & McEvoy, J. W. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88369-6.00042-6 · Cited by 13
Kayani, T., Ahmad, B., Chang, R., Qian, F., Sahinoz, M., Rehan, M., Giaimo, A., Spatz, E. S., & Hu, J. (2024) · Pharmacoepidemiology · doi:10.3390/pharma3010009 · Cited by 9
Zhao, X., Li, J., Tang, X., Liu, R., Xu, J., Xu, L., Jiang, L., Huang, K., Tian, J., Feng, X., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.229 · Cited by 9
The challenge of choosing in cardiovascular risk management
Hoogeveen, R. M., Hanssen, N. M. J., Brouwer, J., Mosterd, A., Tack, C. J., Kroon, A. A., de Borst, G. J., ten Berg, J. M., Trier, T. J. V., van Lennep, J. E. R., et al. (2021) · Netherlands Heart Journal · doi:10.1007/s12471-021-01599-y · Cited by 9
Self-citationGomes, D. J., Wang, S., Goodspeed, L., Turk, K. E., Wietecha, T., Liu, Y.-J., Bornfeldt, K., O’Brien, K. D., Chait, A., & den Hartigh, L. J. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100174 · Cited by 8
Do we need new lipid-lowering agents in the era of PCSK9 inhibitors? Recent advances
Atar, D., Langslet, G., & Tonstad, S. (2022) · Kardiologia Polska · doi:10.33963/kp.a2022.0117 · Cited by 8
Considerations for routinely testing for high Lp(a)
Nurmohamed, N. S., Moriarty, P. M., & Stroes, E. S. G. (2022) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000828 · Cited by 8
Self-citationRuder, S., Mansfield, B. S., Immelman, A., Varki, N. M., Miu, P., Raal, F. J., & Tsimikas, S. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01720-z · Cited by 10
Self-citationSchwarz, A., Demuth, I., Landmesser, U., Haghikia, A., König, M., & Steinhagen‐Thiessen, E. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01708-9 · Cited by 8
Self-citationInnate Immunity in Cardiovascular Diseases—Identification of Novel Molecular Players and Targets
Poller, W. C., Heidecker, B., Ammirati, E., Kuss, A. W., Tzvetkova, A., Poller, W. C., Skurk, C., & Haghikia, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12010335 · Cited by 8
Aortic valve stenosis: the long and winding road
Kronenberg, F. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa1069 · Cited by 9
The Lower the ApoB, the Better: Now, How Does ApoB Fit in the Upcoming Era of Targeted Therapeutics?
Elshazly, M. B., & Quispe, R. (2022) · Circulation · doi:10.1161/circulationaha.122.061188 · Cited by 8
The challenge of reducing residual cardiovascular risk in patients with chronic kidney disease
Nidorf, S. M. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac531 · Cited by 8
Rudin, S., Kriemler, L. F., Dittrich, T. D., Zietz, A., Schweizer, J., Arnold, M., Peters, N., Barinka, F., Jung, S., Arnold, M., et al. (2024) · Swiss Medical Weekly · doi:10.57187/s.3633 · Cited by 7
Dimmeler, S., Ferri, L. D. A. F., Nioi, P., O’Donnell, C. J., Damy, T., Gómez‐Outes, A., Giacca, M., Guo, W., Kavousi, M., Kupatt, C., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf041 · Cited by 7
RNA Therapies in Cardio-Kidney-Metabolic Syndrome: Advancing Disease Management
Mohammadi, A., Karimian, A., Shokri, K., Mohammadi, A., Karzar, N. H., Bahar, R., Radfar, A., Pakyari, M., & Tehrani, B. N. (2025) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-025-10603-4 · Cited by 7
Caruso, P., Liccari, M., Prandin, G., Vinci, P., Pellicori, F., Fiotti, N., Panizon, E., Furlanis, G., Naccarato, M., Biolo, G., et al. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13111-2 · Cited by 7
Lipoprotein(a) in clinical practice: Risk stratification and therapeutic strategies
Nasrallah, N., Atallah, Harb, T., Gerstenblith, G., & Leucker, T. M. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70127 · Cited by 8
A practical guide to the management of dyslipidaemia
Siegel, P. M., Katzmann, J. L., Weinmann‐Menke, J., Landmesser, U., Schunkert, H., Baldus, S. E., Böhm, M., Laufs, U., Lüscher, T. F., & Hilgendorf, I. (2026) · Clinical Research in Cardiology · doi:10.1007/s00392-025-02833-y · Cited by 10
Quantifying the contribution of lipoprotein(a) to all apoB containing particles
Chilazi, M. J., Zheng, W., Park, J., Marvel, F. A., Khoury, S. R., Jones, S. R., & Martin, S. S. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.02.004 · Cited by 7
Treating Cardiovascular Disease with Liver Genome Engineering
Hurley, A. E., & Lagor, W. R. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-00986-z · Cited by 7
Chong, T., Lan, N. S. R., Courtney, W., He, A., Strange, G. A., Playford, D. A., Dwivedi, G., Hillis, G. S., & Ihdayhid, A. R. (2023) · Cardiology in Review · doi:10.1097/crd.0000000000000528 · Cited by 7
Laron, Z., & Werner, H. (2023) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2023.101548 · Cited by 7
Measuring lipoprotein(a) for cardiovascular disease prevention – in whom and when?
Thomas, P. E., Vedel‐Krogh, S., & Nordestgaard, B. G. (2023) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001104 · Cited by 8
Self-citationBaker, B. F., Xia, S., Partridge, W., Engelhardt, J. A., Tsimikas, S., Crooke, S. T., Bhanot, S., & Geary, R. S. (2024) · Nucleic Acid Therapeutics · doi:10.1089/nat.2023.0026 · Cited by 8
Self-citationLp(a) Levels in Relatives of Patients with Acute Coronary Syndrome and Elevated Lp(a): HER(a) Study
Fernández-Olmo, M. R., Bailén, M. C., Quesada, M. M., Mansilla, C. R., Toro, M. M., Suárez, A. L., García, M. L., Quiroga, G. A. C., Bernal, B. C., Cruces, S. O., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13082256 · Cited by 7
Muro, F. M. D., Crociani, M. F., Nardi, G., Ciardetti, N., Biagiotti, L., Bigi, E., Meucci, F., Stolcova, M., Ristalli, F., Cecchi, E., et al. (2024) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.31363 · Cited by 8
Barrios, V., Escobar, C., Anguita, M. P., Esteban, V. I. A., Ruíz, R. C., Cosı́n-Sales, J., Cabello, M. I. E., Martínez, J. M. G., Guijarro, C., Mostaza, J. M., et al. (2021) · REC CardioClinics · doi:10.1016/j.rccl.2021.05.002 · Cited by 7
Filling the gap: Genetic risk assessment in hypercholesterolemia using LDL‐C and LPA genetic scores
Schwaninger, G., Forer, L., Ebenbichler, C. F., Dieplinger, H., Kronenberg, F., Zschocke, J., & Witsch‐Baumgartner, M. (2023) · Clinical Genetics · doi:10.1111/cge.14387 · Cited by 10
Heinrich, N. S., von Scholten, B. J., Reinhard, H., Persson, F., Ahluwalia, T. S., Hansen, T. W., Parving, H., Jacobsen, P. K., & Rossing, P. R. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107593 · Cited by 7
Feldman, D. I., Dudum, R., Alfaddagh, A., Marvel, F. A., Michos, E. D., Blumenthal, R. S., & Martin, S. S. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100027 · Cited by 7
Palanisamy, S., Burka, S., & Blaha, M. J. (2025) · Current Cardiology Reports · doi:10.1007/s11886-025-02210-1 · Cited by 6
Li, C., Jay, N. D., Zhang, S., Fang, X. D., Sharma, S., Catalano, K. A., Sridharan, V., Wang, Z., Zhao, L., Szustakowski, J. D., et al. (2025) · Advanced Genetics · doi:10.1002/ggn2.202500003 · Cited by 7
Ao, L., Noordam, R., Jukema, J. W., van Heemst, D., & van Dijk, K. W. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101008 · Cited by 7
Importance of Clinical, Laboratory, and Genetic Risk Factors for Incident CAD
Bhattacharya, R., Marnell, C. S., Cho, S. M. J., Patel, A. P., Ruan, Y., Koyama, S., Jowell, A. R., Trinder, M., Haidermota, S., Lannery, K., et al. (2025) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.124.004937 · Cited by 7
Gene Therapy Approaches for Atherosclerosis Focusing on Targeting Lipid Metabolism and Inflammation
Bezsonov, E. E., Chernyi, N., Saruhanyan, M., Shimchenko, D., Bondar, N., Gavrilova, D., Baig, M. S., & Malogolovkin, A. S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146950 · Cited by 8
Saito, Y., Tateishi, K., Kato, K., Kitahara, H., & Kobayashi, Y. (2025) · Internal Medicine · doi:10.2169/internalmedicine.5950-25 · Cited by 8
Lipoprotein(a) at a “Tipping Point”: case to move to universal screening
Bhatia, H. S. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101274 · Cited by 6
The role of elevated lipoprotein(a) in aortic valve disease: a systematic review
Wambua, P., Wahinya, M., & Khan, Z. U. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1610395 · Cited by 6
Lipoprotein(a) and Its Role in Peripheral Arterial Disease: A Narrative Review
Mwipatayi, B. P., Dodd, J. E., Bazlee, A. H. A., Stratford, G., Lee, B., Mori, T. A., Watts, G. F., Armari, E., Wong, J., & Schlaich, M. P. (2025) · Vascular Health and Risk Management · doi:10.2147/vhrm.s555127 · Cited by 10
Lipoprotein(a) – treatments in development
Tomlinson, B., & Law, C. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2601062 · Cited by 6
Analytical validation of monoclonal antibody-based ELISA methods for OxPL-apoB and OxPL-apo(a)
Marcovina, S. M., Smith, S., Kornel, J., Yang, X., & Tsimikas, S. (2026) · Journal of Lipid Research · doi:10.1016/j.jlr.2026.100976 · Cited by 8
Self-citationAntibody E06 and the Role of Oxidized Phospholipids in Atherogenesis and Inflammation
Witztum, J. L., Que, X., Tang, W., & Tsimikas, S. (2026) · Circulation Research · doi:10.1161/circresaha.126.327359 · Cited by 6
Self-citationPlasma Biomarker Profiles for Premature and Nonpremature Coronary Heart Disease in Women
Dugani, S. B., Moorthy, M. V., Demler, O., Li, C., Ridker, P. M., Glynn, R. J., & Mora, S. (2024) · Clinical Chemistry · doi:10.1093/clinchem/hvae007 · Cited by 6
Young hearts at risk: Unveiling novel factors in myocardial infarction susceptibility and prevention
Ranjan, A., Agarwal, R. K., Mudgal, S. K., Bhattacharya, S., & Kumar, B. (2024) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_1639_23 · Cited by 7
Efficacy of Traditional Anti-lipidemic Drugs in Lowering Lipoprotein(a) Levels: A Systematic Review
Sinha, M., Maged, R., Tarar, P., Bandi, V. V., Koneru, H. M., & Sarwar, H. (2024) · Cureus · doi:10.7759/cureus.69824 · Cited by 6
Shi, W., Feng, D., Hu, X., Wang, C., Niu, G., Zhao, Z., Zhang, H., Wang, M., & Wu, Y. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.035597 · Cited by 6
Apolipoprotein B modifies the association between lipoprotein(a) and ASCVD risk
Lai, Y., Zhang, S., Guo, Y., Xu, C., Huang, M., Zhan, R., Liu, M., Xiong, Z., Huang, Y., Liao, X., et al. (2024) · American Heart Journal · doi:10.1016/j.ahj.2024.11.014 · Cited by 6
An up-to-date review of emerging biologic therapies for hypercholesterolemia
Tomlinson, B. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2442455 · Cited by 6
Lipoprotein(a) Testing and Emerging Therapies
Mayo-Malasky, P., & Frishman, W. H. (2019) · Cardiology in Review · doi:10.1097/crd.0000000000000295 · Cited by 6
Brandt, E. J., Brandt, D. J., Desai, N. R., Spatz, E. S., Nasir, K., & Mani, A. (2021) · International Journal for Vitamin and Nutrition Research · doi:10.1024/0300-9831/a000709 · Cited by 6
The promise and challenges of RNA-targeted therapeutics in preventive cardiology
Arsenault, B. J. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab462 · Cited by 6
Lipoprotein(a) and the risk of recurrent coronary heart disease: the Dubbo Study
Simons, L. A., & Simons, J. (2023) · Current Medical Research and Opinion · doi:10.1080/03007995.2023.2214434 · Cited by 6
Genetics-based risk scores for prediction of premature coronary artery disease
Gupta, R. (2023) · Indian Heart Journal · doi:10.1016/j.ihj.2023.08.003 · Cited by 7
Is Lipoprotein(a) Clinically Actionable with Today’s Evidence? The Answer is Yes
Ma, G. S., Chiou, T. T., & Wilkinson, M. J. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01937-z · Cited by 5
Yuen, T., Mancini, G. B. J., Hegele, R. A., & Pearson, G. J. (2023) · CJC Open · doi:10.1016/j.cjco.2023.11.015 · Cited by 6
Paragh, G., Zilahi, P., Kolozsvári, L. R., Lőrincz, H., Fülöp, P., & Harangi, M. (2024) · Life · doi:10.3390/life14030374 · Cited by 6
Antisense oligonucleotides for atherosclerotic disease
Bajaj, A., & Rader, D. J. (2020) · Nature Medicine · doi:10.1038/s41591-020-0835-2 · Cited by 6
Chan, D. C., Ying, Q., & Watts, G. F. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000795 · Cited by 6
Tada, H., Kojima, N., Yamagami, K., Nomura, A., Nohara, A., Usui, S., Sakata, K., Fujino, N., Takamura, M., & Kawashiri, M. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100428 · Cited by 6
Motawea, K. R., Elhalag, R. H., Aboelenein, M. M., Ibrahim, N., Swed, S., Fathy, H., Awad, D. M., Belal, M. M., Talat, N. E., Rozan, S. S., et al. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.101746 · Cited by 6
Lipoprotein(a) and Coronary Calcium
Tsimikas, S. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.018 · Cited by 6
Self-citationFlorentin, M., Sagris, D., Tasoudis, P., Korompoki, E., Veltkamp, R. C., D’Anna, L., Wachter, R., Milionis, H. J., & Ntaios, G. (2024) · International Journal of Stroke · doi:10.1177/17474930241292988 · Cited by 5
Krzesińska, A., Marlęga-Linert, J., Chyła-Danił, G., Marcinkowska, M., Rogowska, P., Stumska, K., Fijałkowski, M., Gruchała, M., Jankowski, M., Mickiewicz, A., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413597 · Cited by 5
Maidman, S. D., & Rosenson, R. S. (2025) · BioDrugs · doi:10.1007/s40259-025-00731-3 · Cited by 7
Opposing Metabolic Effects of Growth Hormone and IGF-I: Review and Clinical Implications
Laron, Z., & Werner, H. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf022 · Cited by 6
Henry, D., Baugé, E., Staels, B., & Lalloyer, F. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100086 · Cited by 5
Lepodisiran: Effects on Lipoprotein(a) and Cardiovascular Outcomes in Adults with Elevated Lp(a)
Kattamuri, L. P. V., Sharma, K., & Mukherjee, D. (2025) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/011871529x390148250908045359 · Cited by 5
RNA-based drugs: current, imminent and possible therapeutic applications
Torrisi, S. A., Geraci, F., Diolosà, L., Luca, A. D., Falzone, L., Drago, F., Libra, M., & Leggio, G. M. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108958 · Cited by 8
Enkhmaa, B., Roshanravan, B., & Berglund, L. (2025) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000968 · Cited by 5
Addressing the Lp(a) hypothesis: will lowering Lp(a) decrease the risk of cardiovascular events?
Koschinsky, M. L., & Boffa, M. B. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01278-8 · Cited by 5
Nicholls, S. J., Nelson, A. J., Ray, K. K., Ditmarsch, M., Kling, D., Hsieh, A., Szarek, M. J., Kastelein, J. J. P., & Davidson, M. H. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag399 · Cited by 5
Lipoprotein(a)'s Role in Atherosclerosis and Aortic Stenosis: A Contemporary Literature Review
Obi, M. F., Sharma, M., Ahmad, S., Daim, S. U. R., Kanu, N. T., & Diaz, L. (2024) · Cureus · doi:10.7759/cureus.62984 · Cited by 5
Cancro, F. P., Bellino, M., Silverio, A., Maio, M. D., Esposito, L., Palumbo, R., Manna, M., Formisano, C., Ferruzzi, G. J., Vecchione, C., et al. (2024) · Translational Medicine UniSa · doi:10.37825/2239-9747.1058 · Cited by 5
Oral agents for lowering lipoprotein(a)
Nicholls, S. J., Nelson, A. J., & Michael, L. F. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000953 · Cited by 5
Lian, P., Zhu, W.-Q., Zhao, W.-X., Huang, P., Ran, J., Tang, Y., Huang, X., & Li, R. (2024) · Clinica Chimica Acta · doi:10.1016/j.cca.2024.119982 · Cited by 5
Fujii, E., Ako, J., Takahashi, Y., Toda, M., Iekushi, K., & Yamashita, S. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.64953 · Cited by 5
Comprehensive evaluation of siRNA therapeutics on Lp(a): A network meta‐analysis
Liu, S., Wang, X., Hu, J., Zhao, C., & Qin, X. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16355 · Cited by 6
Lipoprotein(a): An update on its role in human health and disease
Koutsogianni, A.-D., Liberopoulos, E. N., & Tselepis, A. D. (2021) · Journal of Atherosclerosis Prevention and Treatment · doi:10.53590/japt.02.1028 · Cited by 5
Role of Lipoprotein(a) in Cardiovascular Disease: A Review of Clinical Practice
Minami, Y., Kinoshita, D., Muramatsu, Y., Nagata, T., & Ako, J. (2022) · Journal of Asian Pacific Society of Cardiology · doi:10.15420/japsc.2021.31 · Cited by 5
Supporting evidence for lipoprotein(a) measurements in clinical practice
Matveyenko, A., Pavlyha, M., & Reyes‐Soffer, G. (2023) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2023.101746 · Cited by 6
Cui, K., Wu, S., Yin, D., Song, W., Wang, H., Zhu, C., Feng, L., Yang, Y., Fu, R., & Dou, K. (2023) · Cardiology Journal · doi:10.5603/cj.93062 · Cited by 5
Metadata
- Authors
- Tsimikas, S., Karwatowska-Prokopczuk, E., Gouni-Berthold, I., Tardif, J.-C., Baum, S. J., Steinhagen-Thiessen, E., Shapiro, M. D., Stroes, E. S., Moriarty, P. M., Nordestgaard, B. G., Xia, S., Guerriero, J., Viney, N. J., O’Dea, L., & Witztum, J. L.
- Affiliations
- University of Cologne (DE)
- From the Divisions of Cardiovascular Medicine (S.T.) and Endocrinology and Metabolism (J.L.W.), University of California, San Diego, La Jolla, and Ionis Pharmaceuticals, Carlsbad (S.T., S.X., N.J.V.) — both in California; Akcea Therapeutics, Boston (E.K.-P., J.G., L.O.); Polyclinic for Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Cologne, Germany (I.G.-B.); Montreal Heart Institute, Université de Montréal, Montreal (J.-C.T.); Excel Medical Clinical Trials, Boca Raton, FL ...
- Oregon Health & Science University (US)
- University of Copenhagen (DK)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-01-16
- Volume
- 382
- Issue
- 3
- Pages
- 244-255
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2997944188
- Semantic Scholar
- 725c405ccc1ec3726f9ba922da158107891d134f
- Cited by
- 1,094
- References
- 28
- Citations by year
- 2026: 204 · 2025: 176 · 2024: 156 · 2023: 149 · 2022: 159 · 2021: 153 · 2020: 96
- FWCI
- 127.17
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Akcea Therapeutics
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- lipoprotein(a), antisense oligonucleotides, cardiovascular disease, injection site reactions, genetic risk factors
- MeSH terms
- Adult, Aged, Hypolipidemic Agents, Cardiovascular Diseases, Cholesterol, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Middle Aged, Oligonucleotides, Risk Factors, Least-Squares Analysis, Lipoprotein(a), Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
